69.0001.22% ( -0.850 )
Delay Closed: Nov 16, 16:08:11Valuation
Current ValuationThe current P/E ratio is 23.14, above the reasonable range, cheaper than 7.29% of the time in the past 3 years, and the industry ranks 16/78, the industry Median -4.86.
23.14xP/E
HK$69.00Stock price
HK$2.98Earnings per share
23.14xP/E
Stock priceHK$69.00Earnings per shareHK$2.98
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -24.31x
- Typical range
- -44.97x–-13.37x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0152304456608
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
02696HKHENLIUS | 24.48x | 25.47% | HK$24.45B |
02162HKKEYMED BIO-B | 23.14x | 248.55% | HK$20.61B |
02157HKLEPU BIO | 16.88x | 127.52% | HK$4.80B |
06826HKHAOHAI BIOTEC | 28.37x | 128.83% | HK$3.61B |
02181HKMABPHARM-B | 20.51x | -- | HK$2.02B |
06915HKJIANGXI BIO | 20.91x | -- | HK$1.74B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
